Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy

Cancer Letters

Volumn 274, Issue 2, 2009, Pages 187-193

  Tateishi, Yoshihisa ^a   Tatemoto, Yukihiro ^b   Ohno, Seiji ^a   Morishita, Keiko ^a   Ueta, Eisaku ^a   Yamamoto, Tetsuya ^a  

^a KOCHI UNIVERSITY   (Japan)

^b Kochi Health Sciences Center   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase; Laser capture microdissection; Oral squamous cell carcinomas; Thymidine phosphorylate

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; PEPLEOMYCIN; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMATITIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE;

EID: 58149312988     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.010     Document Type: Article

References (32)

1. Taguchi T., and Tsukuda M. Attempts to improve organ preservation in patients with squamous cell carcinoma of the head and neck. Gan To Kagaku Ryoho. 32 (2005) 2030-2034
2. Sapundzhiev N.R., Barth P.J., Vacha P., Dünne A.A., Moll R., Engenhart-Cabillic R., and Werner J.A. Effectiveness of radiochemotherapy on lymph node metastases in patients with stage IV oropharyngeal cancer. Oral Oncol. 40 (2004) 1007-1016
3. Tellez-Bernal E., Belehradek M., Recondo G., Cvitkovic E., Leridant A.M., Verice R., and Armand J.P. Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma. Am. J. Clin. Oncol. 13 (1990) 452-454
4. Hua D., Huang Z.H., Mao Y., and Deng J.Z. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J. Gastroenterol. 13 (2007) 5030-5034
5. Ijuin T., Nibu K., Doi K., Inoue H., Saitoh M., Ohtsuki N., Makino K., and Amatsu M. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer. Acta Otolaryngol. 127 (2007) 305-311
6. Sakurai Y., Kamoshida S., Furuta S., Sunagawa R., Inaba K., Isogaki J., Komori Y., Uyama I., and Tsutsumi Y. Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric Cancer 10 (2007) 234-240
7. Sakamoto E., Nagase H., Kobunai T., Oie S., Oka T., Fukushima M., and Oka T. Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem. Biophys. Res. Commun. 363 (2007) 216-222
8. Kawamura K., Takiguchi N., Wada A., Takenobu H., Kimura H., Soda H., Nagata M., Asano T., and Tagawa M. Up-regulated expression of the uridine phosphorylase gene in human gastric tumors is correlated with a favorable prognosis. Anticancer Res. 26 (2006) 4647-4651
9. Yan R., Wan L., Pizzorno G., and Gao D. Uridine phosphorylase in breast cancer: a new prognostic factor?. Front. Biosci. 11 (2006) 2759-2766
10. Yu Z., Yang Q., Sun J., and Zhen J. Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer. Exp. Oncol. 29 (2007) 192-196
11. Fischel J.L., Etienne M.C., Spector T., Formento P., Renée N., and Milano G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin. Cancer Res. 1 (1995) 991-996
12. Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., Sugihara K., and Hirayama R. Combination of dihydroryrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin. Cancer Res. 9 (2003) 786-791
13. Kobayashi H., Koike T., Nakatsuka A., Kurita H., Sagara J., Taniguchi S., and Kurashina K. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol. 41 (2005) 38-47
14. Saeki H., Ito S., Futatsugi M., Kimura Y., Ohga T., and Sugimachi K. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. Anticancer Res. 22 (2002) 3789-3792
15. Kawasaki G., Yoshitomi I., Yanamoto S., and Mizuno A. Tymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 94 (2002) 717-723
16. Hoque M.O., Kawamata H., Nakashiro K., Omotehara F., Shinagawa Y., Hino S., Begum N.M., Uchida D., Yoshida H., Sato M., and Fujimori T. Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer. Int. J. Oncol. 19 (2001) 953-958
17. Matsubara J., Nishina T., Yamada Y., Moriwaki T., Shimoda T., Kajiwar T., Nakajima T., Kato K., Hamaguchi T., Shimada Y., Okayama Y., Oka T., and Shirao K. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98 (2008) 832-839
18. Takahashi T., Yoshida H., Mamada Y., Taniai N., Mizuguchi Y., Shimizu T., Kakinuma D., Ishikawa Y., Akimaru K., Sugisaki Y., and Tajiri T. Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma. Hepatogastroenterology 54 (2007) 1612-1616
19. Sobin L.H., and Wittekind C.H. UICC: TNM classification of malignant tumors. sixth ed. (2002), Wiley-Liss, New York
20. Willén H., Eklund G., Johnsson J.E., Stendahl U., and Tropé C. Invasive squamous cell carcinoma of the uterine cervix. VIII. Survival and malignancy grading in patients treated by irradiation in Lund 1969-1970. Acta Radiol. Oncol. 24 (1985) 41-50
21. World Health Organization. International Histological Classification of Tumors, second ed., Spinger-Verlag, Berlin, 1988.
22. Shimosato Y., Oboshi S., and Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn. J. Clin. Oncol. 1 (1971) 19-35
23. Lord R.V., Salonga D., Danenberg K.D., Peters J.H., DeMeester T.R., Park J.M., Johansson J., Skinner K.A., Chandrasoma P., DeMeester S.R., Bremne C.G., Tsai P.I., and Danenberg P.V. Telomerasa reverse transcriptase expression is increased early in the Barrett's metaplasia, adenocarcinoma sequence. J. Gastrointest. Surg. 4 (2000) 135-142
24. Kakimoto K., Uetake H., Osanai T., Shirota Y., Takagi Y., Takeshita E., Toriya Y., Danenberg K., Danenberg P.V., and Sugihara K. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett. 223 (2005) 103-111
25. Yamada T., Tanaka N., Yokoi K., Seya T., Kanazawa Y., Koizumi M., Ohaki Y., and Tajiri T. Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. J. Nippon Med .Sch. 75 (2008) 23-27
26. Yoshitomi I., Kawasaki G., Yanamoto S., and Mizuno A. Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil. Oral Oncol. 42 (2006) 880-887
27. Fakhrejahani E., Miyamoto A., and Tanigawa N. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother. Pharmacol. 60 (2007) 437-446
28. Fenoglio-Preiser C.M., Noffsinger A.E., Belli J., and Stemmermann G.N. Pathologic and phenotypic features of gastric cancer. Semin. Oncol. 23 (1996) 292-306
29. Harada K., Kawashima Y., Yoshida H., and Sato M. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Oncol. Rep. 15 (2006) 1417-1423
30. Kocakova I., Svoboda M., Kubosova K., Chrenko V., Roubalova E., Krejci E., Sefr R., Slampa P., Frgala T., and Zaloudik J. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. Neoplasma 54 (2007) 447-453
31. Liersch T., Langer C., Ghadimi B.M., Kulle B., Aust D.E., Baretton G.B., Schwabe W., Häusler P., Becker H., and Jakob C. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J. Clin. Oncol. 24 (2006) 4062-4068
32. Kodera Y., Ito S., Fujiwara M., Mochizuki Y., Nakayama G., Ohashi N., Koike M., Yamamura Y., and Nakao A. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 252 (2007) 307-313